Symbols / ASBP $1.10 +7.84% Aspire Biopharma Holdings, Inc.
ASBP Chart
About
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.53M |
| Enterprise Value | 9.30M | Income | -24.48M | Sales | 6.20K |
| Book/sh | -1.80 | Cash/sh | 0.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 891.09 | P/B | -0.61 | P/C | — |
| EV/EBITDA | — | EV/Sales | 1498.86 | Quick Ratio | 0.13 |
| Current Ratio | 0.17 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -16.38 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -16.57% |
| ROE | — | ROIC | — | Gross Margin | -1.87% |
| Oper. Margin | -3750.45% | Profit Margin | 0.00% | Shs Outstand | 5.02M |
| Shs Float | 4.36M | Short Float | 10.57% | Short Ratio | 2.61 |
| Short Interest | — | 52W High | 35.00 | 52W Low | 0.55 |
| Beta | — | Avg Volume | 1.09M | Volume | 59.24K |
| Target Price | — | Recom | None | Prev Close | $1.02 |
| Price | $1.10 | Change | 7.84% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.13
Latest analyst target
3. DCF / Fair value
$-27.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.13
Low
—
High
—
Mean
—
- ASBP Technical Analysis | Trend, Signals & Chart Patterns | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill hu, 02 Apr 2026 07
- This caffeine powder skips the drink and is heading to stores nationwide - Stock Titan hu, 19 Mar 2026 07
- ASBP stock soars 32% after favorable feedback from FDA for its aspirin – retail expects licensing negotiations soon - MSN ue, 31 Mar 2026 17
- ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits Wed, 07 Jan 2026 08
- ASBP Stock Price, Quote & Chart | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill hu, 02 Apr 2026 07
- Sprinkle-under-tongue caffeine sticks arrive at major 2026 fitness show - Stock Titan hu, 12 Mar 2026 07
- ASPIRE BIOPHARMA HOLDINGS IN (ASBP) Fundamental Analysis & Valuation - ChartMill hu, 02 Apr 2026 07
- $21M cash boost aims to keep Aspire Biopharma on Nasdaq - Stock Titan Wed, 11 Feb 2026 08
- Dry caffeine powder hits c-stores: inside BUZZ BOMB's new 6-pack - Stock Titan ue, 10 Mar 2026 07
- New meclizine powder aims to cut Dramamine wait from an hour to minutes - Stock Titan ue, 17 Feb 2026 08
- Caffeine stick packs hit Palm Springs resorts ahead of Coachella - Stock Titan ue, 03 Feb 2026 08
- FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan Wed, 07 Jan 2026 08
- He drove 70% sales growth at Yerbaé — now Buzz Bomb hires him - Stock Titan ue, 17 Mar 2026 07
- Veteran markets executive joins Aspire to push rapid-onset drug platform - Stock Titan Fri, 13 Feb 2026 08
- Sublingual aspirin powder targets emergency heart attack treatment - Stock Titan hu, 29 Jan 2026 08
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.01
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.01
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
0.01
|
0.00
|
0.00
|
0.00
|
| Reconciled Cost Of Revenue |
|
0.01
|
0.00
|
0.00
|
0.00
|
| Gross Profit |
|
-0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
19.35
+1498.12%
|
1.21
-9.65%
|
1.34
+124.68%
|
0.60
|
| Research And Development |
|
0.92
+540.02%
|
0.14
+100.36%
|
0.07
-58.90%
|
0.18
|
| Selling General And Administration |
|
18.43
+1627.80%
|
1.07
-20.42%
|
1.34
+218.20%
|
0.42
|
| Selling And Marketing Expense |
|
0.79
+526.38%
|
0.13
+218.07%
|
0.04
-12.84%
|
0.05
|
| General And Administrative Expense |
|
17.64
+1775.48%
|
0.94
-29.83%
|
1.34
+256.72%
|
0.38
|
| Other Gand A |
|
17.64
+1775.48%
|
0.94
-29.83%
|
1.34
+256.72%
|
0.38
|
| Total Expenses |
|
19.36
+1498.64%
|
1.21
-9.65%
|
1.34
+124.68%
|
0.60
|
| Operating Income |
|
-19.35
-1498.13%
|
-1.21
+9.65%
|
-1.34
-124.68%
|
-0.60
|
| EBITDA |
|
-15.95
-1217.20%
|
-1.21
-127.07%
|
4.47
+849.89%
|
-0.60
|
| Normalized EBITDA |
|
-15.49
-1179.28%
|
-1.21
-127.07%
|
4.47
+849.89%
|
-0.60
|
| Reconciled Depreciation |
|
—
|
0.00
|
0.00
|
0.00
|
| EBIT |
|
-15.95
-1217.20%
|
-1.21
-127.07%
|
4.47
+849.89%
|
-0.60
|
| Total Unusual Items |
|
-0.46
|
0.00
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-0.46
|
0.00
|
—
|
—
|
| Special Income Charges |
|
-0.36
|
0.00
|
—
|
—
|
| Other Special Charges |
|
0.36
|
—
|
—
|
—
|
| Net Income |
|
-24.48
-1768.95%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Pretax Income |
|
-24.48
-1770.40%
|
-1.31
-129.32%
|
4.46
+848.39%
|
-0.60
|
| Net Non Operating Interest Income Expense |
|
-8.53
-8606.45%
|
-0.10
-101.69%
|
5.80
|
0.00
|
| Interest Expense Non Operating |
|
8.53
+8606.45%
|
0.10
+992.88%
|
0.01
|
0.00
|
| Net Interest Income |
|
-8.53
-8606.45%
|
-0.10
-101.69%
|
5.80
|
0.00
|
| Interest Expense |
|
8.53
+8606.45%
|
0.10
+992.88%
|
0.01
|
0.00
|
| Interest Income Non Operating |
|
—
|
0.55
-90.56%
|
5.81
|
—
|
| Interest Income |
|
—
|
0.55
-90.56%
|
5.81
|
—
|
| Other Income Expense |
|
3.40
+137.36%
|
-9.11
|
—
|
—
|
| Other Non Operating Income Expenses |
|
3.86
+142.40%
|
-9.11
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.10
|
—
|
—
|
—
|
| Tax Provision |
|
0.00
-100.00%
|
0.00
+110.60%
|
0.00
-23.16%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-24.48
-1768.95%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Net Income From Continuing Operation Net Minority Interest |
|
-24.48
-1768.95%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Net Income From Continuing And Discontinued Operation |
|
-24.48
-1768.95%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Net Income Continuous Operations |
|
-24.48
-1768.95%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Normalized Income |
|
-24.02
-1733.89%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Net Income Common Stockholders |
|
-24.48
-1768.95%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Diluted EPS |
|
—
|
-1.14
-129.34%
|
3.88
+847.61%
|
-0.52
|
| Basic EPS |
|
—
|
-1.14
-129.34%
|
3.88
+847.61%
|
-0.52
|
| Basic Average Shares |
|
—
|
1.15
+0.00%
|
1.15
+0.00%
|
1.15
|
| Diluted Average Shares |
|
—
|
1.15
+0.00%
|
1.15
+0.00%
|
1.15
|
| Diluted NI Availto Com Stockholders |
|
-24.48
-1768.95%
|
-1.31
-129.34%
|
4.46
+847.61%
|
-0.60
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1.31
+786.66%
|
0.15
+220.50%
|
0.05
+104.87%
|
0.02
|
| Current Assets |
|
1.31
+786.66%
|
0.15
+220.50%
|
0.05
+104.87%
|
0.02
|
| Cash Cash Equivalents And Short Term Investments |
|
1.00
+27532.92%
|
0.00
-67.49%
|
0.01
+29305.26%
|
0.00
|
| Cash And Cash Equivalents |
|
1.00
+27532.92%
|
0.00
-67.49%
|
0.01
+29305.26%
|
0.00
|
| Cash Financial |
|
1.00
+27532.92%
|
0.00
-67.49%
|
0.01
+29305.26%
|
0.00
|
| Receivables |
|
—
|
0.00
|
0.00
|
0.00
|
| Inventory |
|
0.25
|
0.00
|
—
|
—
|
| Prepaid Assets |
|
0.06
-61.83%
|
0.14
+312.45%
|
0.04
+55.56%
|
0.02
|
| Total Non Current Assets |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
4.97
+1.55%
|
4.90
|
| Total Liabilities Net Minority Interest |
|
7.69
+355.46%
|
1.69
+216.10%
|
0.53
+252.90%
|
0.15
|
| Current Liabilities |
|
7.59
+349.79%
|
1.69
+216.10%
|
0.53
+252.90%
|
0.15
|
| Payables And Accrued Expenses |
|
2.38
+666.11%
|
0.31
+79.55%
|
0.17
+40.77%
|
0.12
|
| Payables |
|
1.37
+341.00%
|
0.31
+79.55%
|
0.17
+40.77%
|
0.12
|
| Accounts Payable |
|
1.01
+226.99%
|
0.31
+79.55%
|
0.17
+40.77%
|
0.12
|
| Current Accrued Expenses |
|
1.01
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
5.18
+308.52%
|
1.27
+251.28%
|
0.36
+1189.51%
|
0.03
|
| Current Debt |
|
5.18
+308.52%
|
1.27
+251.28%
|
0.36
+1189.51%
|
0.03
|
| Other Current Borrowings |
|
3.68
+190.18%
|
1.27
+251.28%
|
0.36
+1189.51%
|
0.03
|
| Other Current Liabilities |
|
0.04
-63.11%
|
0.11
+17635.78%
|
0.00
+0.00%
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.10
|
0.00
|
0.00
-100.00%
|
0.00
|
| Other Non Current Liabilities |
|
—
|
—
|
3.85
0.00%
|
3.85
|
| Stockholders Equity |
|
-6.38
-314.02%
|
-1.54
-215.68%
|
-0.49
-278.80%
|
-0.13
|
| Common Stock Equity |
|
-6.38
-314.02%
|
-1.54
-215.68%
|
-0.49
-278.80%
|
-0.13
|
| Capital Stock |
|
0.00
+411.59%
|
0.00
-99.69%
|
0.02
-90.07%
|
0.22
|
| Common Stock |
|
0.00
+411.59%
|
0.00
-99.69%
|
0.02
-90.07%
|
0.22
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
—
|
| Share Issued |
|
4.00
+247.77%
|
1.15
+0.00%
|
1.15
+0.00%
|
1.15
|
| Ordinary Shares Number |
|
4.00
+247.77%
|
1.15
+0.00%
|
1.15
+0.00%
|
1.15
|
| Additional Paid In Capital |
|
20.88
+1587.96%
|
1.24
+29.20%
|
0.96
+26.32%
|
0.76
|
| Retained Earnings |
|
-27.26
-881.48%
|
-2.78
-89.27%
|
-1.47
-32.40%
|
-1.11
|
| Total Equity Gross Minority Interest |
|
-6.38
-314.02%
|
-1.54
-215.68%
|
-0.49
-278.80%
|
-0.13
|
| Total Capitalization |
|
-6.38
-314.02%
|
-1.54
-215.68%
|
-0.49
-278.80%
|
-0.13
|
| Working Capital |
|
-6.28
-307.81%
|
-1.54
-215.68%
|
-0.49
-278.81%
|
-0.13
|
| Invested Capital |
|
-1.20
-339.54%
|
-0.27
-114.78%
|
-0.13
-26.19%
|
-0.10
|
| Total Debt |
|
5.18
+308.52%
|
1.27
+251.28%
|
0.36
+1189.51%
|
0.03
|
| Net Debt |
|
4.17
+230.22%
|
1.26
+261.47%
|
0.35
+1151.25%
|
0.03
|
| Net Tangible Assets |
|
-6.38
-314.02%
|
-1.54
-215.68%
|
-0.49
-278.80%
|
-0.13
|
| Tangible Book Value |
|
-6.38
-314.02%
|
-1.54
-215.68%
|
-0.49
-278.80%
|
-0.13
|
| Current Notes Payable |
|
1.50
|
0.00
|
—
|
—
|
| Derivative Product Liabilities |
|
0.10
|
0.00
|
—
|
—
|
| Dueto Related Parties Current |
|
0.35
|
0.00
|
—
|
—
|
| Preferred Stock Equity |
|
—
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.92
-1756.62%
|
-0.27
-2481.34%
|
0.01
+107.79%
|
-0.14
|
| Cash Flow From Continuing Operating Activities |
|
-4.92
-1756.62%
|
-0.27
-2481.34%
|
0.01
+107.79%
|
-0.14
|
| Net Income From Continuing Operations |
|
-24.48
-1768.95%
|
-1.31
-264.80%
|
-0.36
+39.87%
|
-0.60
|
| Depreciation Amortization Depletion |
|
—
|
0.00
|
0.00
|
0.00
|
| Depreciation And Amortization |
|
—
|
0.00
|
0.00
|
0.00
|
| Other Non Cash Items |
|
8.29
|
—
|
—
|
—
|
| Stock Based Compensation |
|
14.13
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
-3.40
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-3.77
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.53
-48.94%
|
1.04
+182.19%
|
0.37
-18.49%
|
0.45
|
| Change In Receivables |
|
—
|
0.00
|
0.00
-100.00%
|
0.40
|
| Change In Inventory |
|
-0.25
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.17
+259.35%
|
-0.11
-774.85%
|
-0.01
+44.44%
|
-0.02
|
| Change In Payables And Accrued Expense |
|
0.72
-37.32%
|
1.15
+2206.33%
|
0.05
-65.56%
|
0.15
|
| Change In Accrued Expense |
|
1.05
|
0.00
-100.00%
|
0.08
+78.37%
|
0.04
|
| Change In Payable |
|
-0.32
-128.06%
|
1.15
+2206.33%
|
0.05
-51.29%
|
0.10
|
| Change In Account Payable |
|
-0.32
-230.64%
|
0.25
+395.32%
|
0.05
-51.29%
|
0.10
|
| Change In Other Current Liabilities |
|
-0.11
|
0.00
-100.00%
|
0.33
+585.11%
|
-0.07
|
| Investing Cash Flow |
|
—
|
0.00
|
0.00
+100.00%
|
-4.90
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
-0.08
+98.45%
|
-4.90
|
| Capital Expenditure |
|
—
|
—
|
-0.08
+98.45%
|
-4.90
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
-0.08
+98.45%
|
-4.90
|
| Financing Cash Flow |
|
5.92
+2199.19%
|
0.26
|
0.00
-100.00%
|
4.85
|
| Cash Flow From Continuing Financing Activities |
|
5.92
+2199.19%
|
0.26
|
0.00
-100.00%
|
4.85
|
| Net Issuance Payments Of Debt |
|
6.57
|
0.00
|
—
|
—
|
| Issuance Of Debt |
|
10.30
|
0.00
|
—
|
—
|
| Repayment Of Debt |
|
-3.73
|
0.00
|
—
|
—
|
| Short Term Debt Issuance |
|
10.30
|
0.00
|
—
|
—
|
| Short Term Debt Payments |
|
-3.73
|
0.00
|
—
|
—
|
| Net Short Term Debt Issuance |
|
6.57
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
0.27
+3.18%
|
0.26
|
0.00
-100.00%
|
1.00
|
| Net Other Financing Charges |
|
-0.91
|
—
|
—
|
3.85
|
| Changes In Cash |
|
1.00
+13364.43%
|
-0.01
-167.72%
|
0.01
+106.00%
|
-0.19
|
| Beginning Cash Position |
|
0.00
-67.49%
|
0.01
+29305.26%
|
0.00
-99.98%
|
0.19
|
| End Cash Position |
|
1.00
+27532.92%
|
0.00
-67.49%
|
0.01
+29305.26%
|
0.00
|
| Free Cash Flow |
|
-4.92
-1756.62%
|
-0.27
-2481.34%
|
0.01
+100.22%
|
-5.04
|
| Interest Paid Supplemental Data |
|
0.04
|
0.00
|
0.00
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
|
0.00
|
—
|
| Common Stock Issuance |
|
0.27
+3.18%
|
0.26
|
0.00
-100.00%
|
1.00
|
| Issuance Of Capital Stock |
|
0.27
+3.18%
|
0.26
|
0.00
-100.00%
|
1.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-30 View
- 8-K2026-02-12 View
- 8-K2026-02-06 View
- 8-K2026-01-30 View
- 8-K2026-01-15 View
- 8-K2026-01-13 View
- 8-K2026-01-06 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-11-05 View
- 8-K2025-10-17 View
- 8-K2025-09-26 View
- 8-K2025-08-22 View
- 10-Q2025-08-13 View
- 8-K2025-07-30 View
- 8-K2025-06-18 View
- 8-K2025-06-10 View
- 42025-06-06 View
- 10-Q2025-05-14 View
- 8-K2025-04-30 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|